Fibrate use was associated with new onset CKD, but a lower risk for kidney failure. Fibrate therapy may lower the risks of mortality and progression to end-stage kidney disease (ESKD), despite raising ...

The major finding is the CV benefit. Fibrates seem to be much more potent in people with kidney disease, and this is important. Thus, overall, the results suggest that fibrates could be used more ...

Background Fibrates has been extensively used to improve plasma lipid levels and prevent adverse cardiovascular outcomes. However, the effect of fibrates on stroke is unclear at the present time. We ...

In a real-world Japanese study, recent fibrate use was associated with decreased odds of MACE among patients with CKD. Recent fibrate use is associated with reduced risks for major adverse ...